Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

Apogee Therapeutics recently reported a higher full-year 2025 net loss of US$255.84 million and a wider basic loss per share, while also filing a US$287.29 million common stock shelf registration and ...

Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

Apogee Therapeutics (NASDAQ:APGE) is one of the 17 biotechnology stocks with more than 50% upside. On January 25, Citi analyst Geoff Meacham maintained a Buy rating on Apogee Therapeutics (NASDAQ:APGE ...

Investors in Apogee Therapeutics Inc (Symbol: APGE) saw new options become available today, for the December 2025 expiration. One of the key data points that goes into the price an option buyer is ...

Apogee Therapeutics Inc. (NASDAQ:APGE) stock is experiencing a significant surge, trading almost 29% higher in premarket on Monday. This substantial increase in stock price follows the release of ...

Investors in Apogee Therapeutics Inc (Symbol: APGE) saw new options become available this week, for the October 17th expiration. One of the key inputs that goes into the price an option buyer is ...

Apogee Therapeutics, Inc. (NASDAQ:APGE) on Monday revealed interim data from its Phase 1b trial of APG808, a novel half-life extended IL-4Rα antibody, in patients with mild-to-moderate asthma. The ...